Does Wegovy Have GLP-1? How Semaglutide Works in the Body

Step 1: what GLP-1 is and why Wegovy uses it

GLP-1 stands for glucagon-like peptide-1. Your intestines release it naturally within minutes of eating, and it does several things at once: it tells the pancreas to release insulin, signals the brain that you have eaten, and slows the speed at which the stomach empties its contents into the small bowel. The catch is that natural GLP-1 breaks down in the bloodstream within a few minutes, so its effects are brief.

Semaglutide solves that by being a chemically modified analogue of GLP-1, built to resist the enzyme that ordinarily destroys it. The result is a molecule that behaves like GLP-1 but lingers for about a week, long enough for a single weekly injection to maintain a sustained effect. If you want to go deeper on semaglutide's pharmacology, the semaglutide overview on this site covers the full picture alongside the licensed indications.

Wegovy, then, is not a source of GLP-1 itself; it is a compound that activates the receptor GLP-1 would normally activate, but for far longer. That distinction matters when patients ask whether they are taking a hormone, they are taking a receptor agonist, which is a related but meaningfully different thing.

Step 2: what happens at the GLP-1 receptor once semaglutide binds

Once semaglutide reaches the GLP-1 receptor, it triggers a cascade worth understanding. In the gut, gastric emptying slows, so food stays in the stomach longer and feelings of fullness last further into the day. In the brain's hypothalamus, appetite-regulating centres receive reduced hunger signals, and many people find they are simply less preoccupied with food between meals. The pancreas releases more insulin in response to glucose and less glucagon (the hormone that raises blood sugar), which helps post-meal spikes flatten out.

These effects compound across weeks. Clinical trial data published in the New England Journal of Medicine (STEP 1) showed an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, in adults with obesity and no diabetes. The relationship between semaglutide and GLP-1 is explored further if you want to compare the receptor science in more detail.

A quick check worth doing: look at the patient information leaflet inside your Wegovy box. The active ingredient section confirms semaglutide and its receptor classification, it takes under a minute and gives you the primary source directly.

Step 3: how Wegovy's GLP-1 profile compares to other medicines in the same class

Semaglutide is not the only GLP-1 receptor agonist. Ozempic is also semaglutide, but licensed for type 2 diabetes rather than weight management, the two should not be conflated, and Ozempic is not prescribed by UK clinicians for weight loss. Tirzepatide (Mounjaro) adds a second receptor target, GIP, alongside GLP-1 activation. That dual action is the central difference between the two licensed weight-management injectables currently available in the UK. The page on whether Wegovy activates GIP receptors explains why that distinction matters clinically.

Wegovy also now exists in a higher 7.2 mg dose, approved by the MHRA in early 2026, which trial data suggest narrows the average weight-loss gap with the highest tirzepatide dose. The Wegovy treatment page covers the current licensed dose range and what that approval means in practice. On the oral side, the MHRA approved Wegovy tablets (oral semaglutide for weight management) in June 2026, the same GLP-1 mechanism delivered daily as a tablet rather than a weekly injection, for those who prefer not to inject.

All of these options are prescription-only medicines. The NHS covers their use under specific, phased eligibility criteria outlined in NICE technology appraisal TA875, which sets out when semaglutide is recommended within specialist weight management services. For those who do not meet the current NHS thresholds or who prefer not to wait, private prescribing through a regulated pharmacy is the alternative, with the same clinical oversight requirement. The cost context for Wegovy walks through what private treatment typically includes and why headline prices can vary.

Step 4: what GLP-1 activation does not do, and the safety picture

A GLP-1 receptor agonist is not a stimulant, a fat-burner or a metabolism booster in the traditional sense. It works primarily through appetite and satiety pathways, and results depend on it being used alongside a reduced-calorie diet and regular physical activity, as the licence requires. It does not override biology completely; individual responses vary, and no medicine produces identical outcomes across everyone.

The most common side effects follow from the GI mechanism: nausea, changes in bowel habit, indigestion and fatigue tend to appear early in treatment, particularly after a dose increase, and often ease within a couple of weeks as the body adjusts. Pancreatitis is an infrequent but serious risk, the MHRA flagged this in a Drug Safety Update published in January 2026, advising anyone who develops severe stomach pain that radiates to the back to seek medical help promptly. Wegovy is not licensed for use during pregnancy, while breastfeeding, or when trying to conceive, and is not suitable for under-18s. A prescriber reviews your full health picture before any treatment starts, that assessment is the mechanism by which these risks are managed individually.

If you have further questions about the ingredients or formulation, the full ingredients breakdown for Wegovy goes through the excipients alongside the active compound. And if you are ready to find out whether you are eligible, a free consultation with a GPhC-registered prescriber is the right next step.